Literature DB >> 31692073

Snx10 and PIKfyve are required for lysosome formation in osteoclasts.

Farhath Sultana1, Leslie R Morse1, Gabriela Picotto2, Weimin Liu3, Prakash K Jha1, Paul R Odgren4, Ricardo A Battaglino1.   

Abstract

Bone resorption and organelle homeostasis in osteoclasts require specialized intracellular trafficking. Sorting nexin 10 (Snx10) is a member of the sorting nexin family of proteins that plays crucial roles in cargo sorting in the endosomal pathway by its binding to phosphoinositide(3)phosphate (PI3P) localized in early endosomes. We and others have shown previously that the gene encoding sorting Snx10 is required for osteoclast morphogenesis and function, as osteoclasts from humans and mice lacking functional Snx10 are dysfunctional. To better understand the role and mechanisms by which Snx10 regulates vesicular transport, the aim of the present work was to study PIKfyve, another PI3P-binding protein, which phosphorylates PI3P to PI(3,5)P2. PI(3,5)P2 is known to be required for endosome/lysosome maturation, and the inhibition of PIKfyve causes endosome enlargement. Overexpression of Snx10 also induces accumulation of early endosomes suggesting that both Snx10 and PIKfyve are required for normal endosome/lysosome transition. Apilimod is a small molecule with specific, nanomolar inhibitory activity on PIKfyve but only in the presence of key osteoclast factors CLCN7, OSTM1, and Snx10. This observation suggests that apilimod's inhibitory effects are mediated by endosome/lysosome disruption. Here we show that both Snx10 and PIKfyve colocalize to early endosomes in osteoclasts and coimmunoprecipitate in vesicle fractions. Treatment with 10 nM apilimod or genetic deletion of PIKfyve in cells resulted in the accumulation of early endosomes, and in the inhibition of osteoclast differentiation, lysosome formation, and secretion of TRAP from differentiated osteoclasts. Snx10 and PIKfyve also colocalized in gastric zymogenic cells, another cell type impacted by Snx10 mutations. Apilimod-specific inhibition of PIKfyve required Snx10 expression, as it did not inhibit lysosome biogenesis in Snx10-deficient osteoclasts. These findings suggest that Snx10 and PIKfyve are involved in the regulation of endosome/lysosome homeostasis via the synthesis of PI(3,5)P2 and may point to a new strategy to prevent bone loss.
© 2019 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31692073     DOI: 10.1002/jcb.29534

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

Review 1.  Ostm1 from Mouse to Human: Insights into Osteoclast Maturation.

Authors:  Jean Vacher; Michael Bruccoleri; Monica Pata
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

2.  Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

Authors:  Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Lars Pache; Sebastian Burgstaller-Muehlbacher; Paul D De Jesus; Peter Teriete; Mitchell V Hull; Max W Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina M Herbert; Kuoyuan Cheng; Tu-Trinh H Nguyen; Andrey Rubanov; Yuan Pu; Courtney Nguyen; Angela Choi; Raveen Rathnasinghe; Michael Schotsaert; Lisa Miorin; Marion Dejosez; Thomas P Zwaka; Ko-Yung Sit; Luis Martinez-Sobrido; Wen-Chun Liu; Kris M White; Mackenzie E Chapman; Emma K Lendy; Richard J Glynne; Randy Albrecht; Eytan Ruppin; Andrew D Mesecar; Jeffrey R Johnson; Christopher Benner; Ren Sun; Peter G Schultz; Andrew I Su; Adolfo García-Sastre; Arnab K Chatterjee; Kwok-Yung Yuen; Sumit K Chanda
Journal:  Nature       Date:  2020-07-24       Impact factor: 69.504

3.  Sorting Nexin 10 as a Key Regulator of Membrane Trafficking in Bone-Resorbing Osteoclasts: Lessons Learned From Osteopetrosis.

Authors:  Ari Elson; Merle Stein; Grace Rabie; Maayan Barnea-Zohar; Sabina Winograd-Katz; Nina Reuven; Moran Shalev; Juraj Sekeres; Moien Kanaan; Jan Tuckermann; Benjamin Geiger
Journal:  Front Cell Dev Biol       Date:  2021-05-20

4.  Inhibition of PIKfyve Ameliorates the Proliferation and Migration of Vascular Smooth Muscle Cells and Vascular Intima Hyperplasia By Reducing mTORC1 Activity.

Authors:  Min Gu; Zhen Wang; Feifei Feng; Yongjian Yang; Xiongshan Sun; Dachun Yang
Journal:  J Cardiovasc Pharmacol       Date:  2022-05-01       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.